Caring Brands Inc. acquires exclusive rights to Emesyl for global distribution, enhancing its OTC health product portfolio.
Quiver AI Summary
Caring Brands Inc. has announced a worldwide exclusive license agreement with Itonis Inc. for the over-the-counter nausea relief product Emesyl. This agreement allows Caring Brands to take full control of the manufacturing, marketing, and distribution of Emesyl, with Itonis providing necessary technical and product details to support this venture. The global market for nausea treatments is expected to exceed $6.23 billion in 2025, highlighting the potential of Emesyl in this landscape. Caring Brands' CEO Glynn Wilson expressed excitement over this milestone, which aligns with the company's strategy to enhance its OTC product portfolio. The agreement also includes a royalty structure based on future sales and potential equity in Itonis related to revenue milestones. The company plans to share more details about product development and marketing efforts in the near future.
Potential Positives
- Caring Brands Inc. has secured an exclusive worldwide license for Emesyl, a recognized OTC nausea relief product, enhancing its health and wellness portfolio.
- The global market for nausea treatment is projected to exceed USD 6.23 billion in 2025, indicating strong commercial potential for Emesyl.
- The agreement allows Caring Brands to oversee all aspects of Emesyl's commercialization, including manufacturing, marketing, and global distribution, which could lead to increased revenue streams.
- Caring Brands will benefit from a royalty structure based on future net sales and the potential for equity in Itonis tied to revenue milestones, aligning with their growth strategy.
Potential Negatives
- The company is assuming full responsibility for product manufacturing, marketing, and global distribution of Emesyl, which could pose significant operational and financial risks if the product does not perform as anticipated.
- Investors may be cautious due to the reliance on forward-looking statements, which contain inherent risks and uncertainties that could materially affect anticipated results.
- There is no assurance that Caring Brands will successfully revitalize Emesyl's market presence, which raises concerns about the viability of this major strategic move.
FAQ
What is the exclusive agreement between Caring Brands and Itonis?
Caring Brands has secured exclusive worldwide rights to manufacture, market, and distribute the nausea relief product Emesyl from Itonis.
How does Caring Brands plan to commercialize Emesyl?
Caring Brands will oversee product manufacturing, marketing, sales strategy, and global distribution of Emesyl to enhance its market presence.
What is the market potential for nausea relief products?
The global market for nausea treatment and related therapies is projected to exceed USD 6.23 billion by 2025, highlighting significant commercial opportunities.
What role does Itonis play in this agreement?
Itonis will support Caring Brands by providing technical information, product formulation data, historical sales information, and intellectual property details.
What future products does Caring Brands plan to launch?
Caring Brands intends to launch five unique products over the next two years, expanding its health and wellness portfolio significantly.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
Full Release
Jupiter, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Caring Brands Inc. (Nasdaq: CABR) today announced that it has entered into an exclusive worldwide license agreement with Itonis Inc. to manufacture, market, and distribute Emesyl, Itonis’s over-the-counter (OTC) nausea relief product. The agreement provides Caring Brands with full rights to commercialize Emesyl and to oversee all manufacturing activities associated with the product.
Under the terms of the agreement, Caring Brands will assume responsibility for product manufacturing, marketing, sales strategy, and global distribution. Itonis will provide technical information, product formulation data, historical sales information, and intellectual property details to support Caring Brands’ commercial launch and ongoing development efforts.
According to QY Research , the global market for nausea treatment and related therapies is projected to exceed USD 6.23 billion in 2025, underscoring the broader commercial context for the Emesyl license.
Glynn Wilson, CEO of Caring Brands Inc., said, “Securing the exclusive rights to Emesyl marks an important milestone for Caring Brands as we expand our health and wellness portfolio. Emesyl brings a recognized product with real commercial potential, and we look forward to revitalizing and scaling its market presence. This agreement aligns perfectly with our long‑term strategy for OTC products, and we are excited to share more about our upcoming plans in the months ahead.”
The agreement includes a royalty structure based on future net sales, along with the potential for Caring Brands to earn equity in Itonis tied to revenue milestones. Caring Brands expects to provide further updates on product timelines, manufacturing progress, and commercial rollout as these initiatives advance.
About Caring Brands
Caring Brands Inc. has a growing portfolio of unique, patented, and clinically validated products for skin and hair growth. The Company intends to launch a total of 5 products over the next 2 years in addition to in-licensing additional products. Management has a successful track record of strategic acquisitions, rapid product development, IP development and product licensing. Revenues from the sales of Hair Enzyme Booster for the treatment of hair loss, and Photocil for the treatment of psoriasis and vitiligo, are currently being generated by direct sales in the US and licensees in India. Additional product opportunities include CB-101 for the treatment of eczema, NoStingz, a sunscreen that prevents jellyfish stings.
Contact :
Brian S John
Chief Investment Officer
(561) 896-7616
Forward-Looking Statements
This communication contains forward-looking statements regarding Caring Brands, Inc., including, the anticipated timing of studies and the results and benefits thereof. You can generally identify forward-looking statements by the use of forward-looking terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “explore,” “evaluate,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” or “will,” or the negative thereof or other variations thereon or comparable terminology. These forward-looking statements are based on each of the Company’s current plans, objectives, estimates, expectations, and intentions and inherently involve significant risks and uncertainties, many of which are beyond our control. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties and other risks and uncertainties affecting Caring Brands, Inc.. Moreover, other risks and uncertainties of which the combined company is not currently aware may also affect each of the companies’ forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. Investors are cautioned that forward-looking statements are not guarantees of future performance. The forward-looking statements made in this communication are made only as of the date hereof or as of the dates indicated in the forward-looking statements and reflect the views stated therein with respect to future events at such dates, even if they are subsequently made available by Caring Brands, Inc. on its website or otherwise. Caring Brands, Inc. undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.